Page header

Recommendation of the President – Redemplo (plozasiran)

On 30 April 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 54/2026 on the appropriateness of granting approval for the reimbursement of the medicinal product Redemplo (plozasiran) for the indication: familial chylomicronemia syndrome

Publication in Public Information Bulletin (BIP) >>